# Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

> **NCT00877149** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (estimated)

## Conditions studied

- Compensated Chronic Hepatitis B

## Interventions

- **DRUG:** telbivudine/LDT600

## Key facts

- **NCT ID:** NCT00877149
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2012-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00877149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00877149, "Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00877149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*